Completed PHASE1 INTERVENTIONAL 1-arm NCT01910480

Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

A Phase 1, Open-Label Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

Sponsor: Neurocrine Biosciences

Conditions Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects

Interventions Ketoconazole 400 mg (200 mg twice daily) NBI-98854 50 mg capsule once daily

Updated 6 times since 2017 Last updated: Sep 3, 2013 Started: Jul 31, 2013 Primary completion: Aug 31, 2013 Completion: Aug 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01910480, this PHASE1 trial focuses on Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects and remains completed. Sponsored by Neurocrine Biosciences, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Neurocrine Biosciences

Data source: Neurocrine Biosciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tempe, United States